» Articles » PMID: 28157093

BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants

Abstract

The β-site amyloid-β protein precursor (AβPP) cleaving enzyme-1 (BACE1) is the rate limiting enzyme in the generation of amyloid-β peptide (Aβ) from AβPP, one of the major pathways in Alzheimer's disease (AD) pathology. Increased BACE1 levels and activity have been reported in the brain of patients with sporadic AD. Therefore, changes of BACE1 levels in the cerebrospinal fluid (CSF) have also been investigated as a possible biomarker of the disease. We analyzed BACE1 levels in CSF of elderly healthy participants before and after chronic treatment with a BACE inhibitor (BACEi) and evaluated the correlation between BACE1 levels and downstream AD markers. Overall, BACE1 CSF levels showed strong correlations to all downstream AD markers investigated. This is the first reported finding that shows BACE1 levels in CSF were well correlated to its end product Aβ1 - 42. As previously described, BACE1 levels were strongly correlated to total-tau and phosphorylated tau levels in CSF. Generally, chronic BACE inhibition did not influence BACE1 CSF protein levels. Follow-up studies including early-stage AD pathophysiology and prodromal AD patients will help to understand the importance of measuring BACE1 routinely in daily clinical practice and AD clinical trials.

Citing Articles

Review on anti-alzheimer drug development: approaches, challenges and perspectives.

Abdallah A RSC Adv. 2024; 14(16):11057-11088.

PMID: 38586442 PMC: 10995770. DOI: 10.1039/d3ra08333k.


BACE1 Inhibitors for Alzheimer's Disease: The Past, Present and Any Future?.

Bazzari F, Bazzari A Molecules. 2022; 27(24).

PMID: 36557955 PMC: 9785888. DOI: 10.3390/molecules27248823.


P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles.

Wesenhagen K, Tijms B, Boonkamp L, Hoede P, Goossens J, Dewit N Alzheimers Res Ther. 2022; 14(1):95.

PMID: 35841015 PMC: 9288016. DOI: 10.1186/s13195-022-01038-z.


Integrated Analysis of Weighted Gene Coexpression Network Analysis Identifying Six Genes as Novel Biomarkers for Alzheimer's Disease.

Zhang T, Liu N, Wei W, Zhang Z, Li H Oxid Med Cell Longev. 2021; 2021:9918498.

PMID: 34367470 PMC: 8339876. DOI: 10.1155/2021/9918498.


Onset of Preclinical Alzheimer Disease in Monozygotic Twins.

Konijnenberg E, Tomassen J, den Braber A, Ten Kate M, Yaqub M, Mulder S Ann Neurol. 2021; 89(5):987-1000.

PMID: 33583080 PMC: 8251701. DOI: 10.1002/ana.26048.


References
1.
Vassar R, Bennett B, Kahn S, Mendiaz E, Denis P, Teplow D . Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999; 286(5440):735-41. DOI: 10.1126/science.286.5440.735. View

2.
Sinha S, Anderson J, Barbour R, Basi G, Caccavello R, Davis D . Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature. 1999; 402(6761):537-40. DOI: 10.1038/990114. View

3.
Holsinger R, McLean C, Beyreuther K, Masters C, Evin G . Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol. 2002; 51(6):783-6. DOI: 10.1002/ana.10208. View

4.
Hesse C, Rosengren L, Vanmechelen E, Vanderstichele H, Jensen C, Davidsson P . Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimers Dis. 2002; 2(3-4):199-206. DOI: 10.3233/jad-2000-23-402. View

5.
Fukumoto H, Cheung B, Hyman B, Irizarry M . Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol. 2002; 59(9):1381-9. DOI: 10.1001/archneur.59.9.1381. View